1. Home
  2. CGEM vs PDS Comparison

CGEM vs PDS Comparison

Compare CGEM & PDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$20.38

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Logo Precision Drilling Corporation

PDS

Precision Drilling Corporation

N/A

Current Price

$88.02

Market Cap

1.1B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CGEM
PDS
Founded
2016
1951
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
2020
1998

Fundamental Metrics

Financial Performance
Metric
CGEM
PDS
Price
$20.38
$88.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
$30.13
$122.33
AVG Volume (30 Days)
742.2K
72.6K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$5.66
Revenue Next Year
$5.20
$2.31
P/E Ratio
N/A
$884.15
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$53.45
52 Week High
$23.19
$103.80

Technical Indicators

Market Signals
Indicator
CGEM
PDS
Relative Strength Index (RSI) 48.20 53.64
Support Level $11.87 $86.74
Resistance Level $23.19 $93.20
Average True Range (ATR) 1.01 2.89
MACD -0.35 -0.54
Stochastic Oscillator 43.38 43.41

Price Performance

Historical Comparison
CGEM
PDS

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About PDS Precision Drilling Corporation

Precision Drilling Corp is a provider of contract drilling, completion, and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. The company operates through two industry segments: Contract Drilling Services, which generates maximum revenue and includes drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale, and repair of drilling equipment; and Completion and Production Services, which includes service rigs, oilfield equipment rental, and camp services. The company generates the majority of its revenue from the United States.

Share on Social Networks: